DxS and AstraZeneca Collaborate on Iressa® Diagnostic
Taskin Ahmed
Abstract
DxS, a personalised medicine company has inked an agreement with AstraZeneca to commercialise its TheraScreen EGFR29 as a companion diagnostic kit with AstraZeneca’s non-small cell lung cancer drug, Iressa® (gefitnib).
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.